New oral drug aims to restore skin color in vitiligo
NCT ID NCT07712523
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This trial tests an experimental drug called QY201 in adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants take QY201 or a placebo tablet twice daily for 24 weeks. The main goal is to see if QY201 can reduce the amount of facial skin affected by vitiligo, helping guide the dose for future larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called QY201, taken as a tablet twice daily
- What this could lead to
- If successful, this could lead to a new oral treatment option for vitiligo, helping restore skin color.
- What could go wrong
- This is an early Phase 2 trial with only 200 participants, so results may not confirm effectiveness or safety in larger groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT SUBJECTS WITH NON-SEGMENTAL VITILIGO are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110002, China